Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
- Conditions
- Helicobacter Pylori Eradication Antibiotic
- Interventions
- Drug: Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
- Registration Number
- NCT02835560
- Lead Sponsor
- Livzon Pharmaceutical Group Inc.
- Brief Summary
This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID on the first line eradication treatment of H.pylori.
Participants are defined as persons who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage), gastritis and dyspepsia confirmed to be H.pylori positive patients in the biopsy and UBT test. For 14 days, participants treated as Esoprazole based bismuth-containing quadruple regimen therapy therapy including Esoprazole 20mg, Bismuth Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID. After treatment, the healing rate was evaluated in the UBT test and Biopsy at 49±5days from the first day dosing.
- Detailed Description
This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg，Clarithromycin 500mg and Amoxicillin Cap(Amoxicillin) 1000mg BID on the first line eradication treatment of H.pylori.
Participants are defined as persons who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage), gastritis and dyspepsia confirmed to be H.pylori positive patients in the biopsy and UBT test. For 14 days, Participants treated as Esoprazole based bismuth-containing quadruple regimen therapy therapy including Esoprazole 20mg, Bismuth Potassium Citrate 220mg，Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID. After treatment, The healing rate was evaluated in the UBT test and Biopsy at 49±5days from the first day dosing.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar) or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.
- Subject who fully understands conditions of clinical trial.
- Subject who agrees to participate and spontaneously sign the ICF.
- Known hypersensitivity to any component of ilaprazole, Amoxicillin and Levofloxacin.
- Subjects who are taking contraindicated medications for experimental and concomitant drug.
- Patients with abnormal levels in the laboratory tests.
- Total Bilirubin, Creatinine> 1.5 times upper limit of normal.
- AST, ALT, Alkaline phosphatase, BUN> 2 times upper limit of normal.
- Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of the study.
- Pregnant and/or lactating women.
- Reproductive aged women not using contraception.
- Uncontrolled diabetics.
- Uncontrolled hypertension.
- Uncontrolled liver dysfunction.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid Active Comparator Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy Esoprazole Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid
- Primary Outcome Measures
Name Time Method Eradication rate of Helicobacter pylori as assessed by UBT test up to 2 months
- Secondary Outcome Measures
Name Time Method